Introduction:
The expansion is geared towards enhancing production capabilities for the current and future portfolio focused on serious chronic diseases.
Features:
Key features of the expansion include aseptic production, additional finished production processes, and an extension of the Quality Control Laboratory.
The investment is specifically designed to accommodate GLP-1 products, aiming to address the increasing demand for innovative medicines.
The expanded facilities will more than double the current site's footprint, adopting a multi-product facility approach for versatility.
The design incorporates state-of-the-art technology and a modern working environment, ensuring a future-proof and cost-effective facility.
The investment is expected to create over 500 new jobs, supporting 24/7 production activities upon completion.
During the construction phase, up to 2,000 external employees will be engaged in the project, highlighting its scale and significance.
This initiative reflects Novo Nordisk's commitment to advancing pharmaceutical production, job creation, and sustainable practices.
Construction has commenced and is scheduled for gradual completion between 2026 and 2028.
Specifications:
Name Novo Nordisk
Type Expansion
Year 2028
